Irritable bowel syndrome (IBS) is a chronic, functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits, such as diarrhea, constipation, or mixed stool patterns. Despite normal findings on routine laboratory tests and structural imaging, IBS reflects dysregulated gut–brain interaction, involving visceral hypersensitivity, altered intestinal motility, and changes in mucosal and microbial physiology. IBS is clinically important because it drives recurrent symptoms, affects quality of life, and often coexists with psychological distress, including anxiety or depression, though the disorder is not simply a primary mental illness.
Epidemiologically, IBS is common in primary care and gastroenterology settings, with symptom prevalence that varies by diagnostic criteria and population sampling. Many patients experience symptom onset in adolescence or early adulthood, but the course can fluctuate over years. IBS is typically categorized by stool pattern using the Rome classification: IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), IBS with mixed bowel habits (IBS-M), and unclassified IBS (IBS-U). These phenotypes are clinically relevant because they predict treatment response and side-effect profiles.
The pathophysiology is multifactorial. Visceral hypersensitivity is central: patients exhibit heightened pain perception due to altered afferent signaling from the gut to the central nervous system, mediated by changes in neurotransmitters and spinal/brainstem processing. Intestinal motility abnormalities contribute to urgency or constipation via dysregulation of enteric neural circuits and smooth muscle function. Inflammation at low, subclinical levels may be present in a subset, including post-infectious IBS where an initial gastrointestinal infection can lead to persistent immune signaling and barrier dysfunction. The gut microbiome also plays a role; microbial shifts can influence fermentation products, bile acid metabolism, epithelial barrier integrity, and immune modulation. Finally, psychosocial stress can alter autonomic and hormonal pathways (e.g., hypothalamic–pituitary–adrenal axis signaling), thereby amplifying symptom severity through bidirectional communication between the gut and the brain.
Clinically, IBS requires careful differentiation from alarm conditions such as inflammatory bowel disease, colorectal cancer, celiac disease, and malabsorption syndromes. The diagnostic approach emphasizes symptom criteria plus exclusion of red flags: unintentional weight loss, gastrointestinal bleeding, anemia, nocturnal symptoms, family history of colorectal cancer or IBD, fever, and onset after age 50 without prior history. The Rome IV framework supports IBS diagnosis based on recurrent abdominal pain at least one day per week for at least three months, associated with two or more features including relation to defecation, change in stool frequency, or change in stool form.
Initial evaluation often includes basic laboratory tests tailored to risk and phenotype: complete blood count, inflammatory markers (such as C-reactive protein), celiac serology in appropriate settings, and stool studies when diarrhea predominates or when infection is plausible. Colonoscopy is indicated for patients with alarm features, high-risk profiles, or persistent symptoms meeting guideline criteria based on age and regional practice.
Treatment is individualized and typically multimodal. Dietary interventions include a trial of a low-FODMAP diet to reduce fermentable oligo-, di-, mono-saccharides and polyols that can increase osmotic load and gas production, thereby worsening pain and stool changes. Soluble fiber (e.g., psyllium) can improve global symptoms, particularly in IBS-C and mixed IBS. Pharmacotherapy is phenotype-driven: antispasmodics may reduce cramping; osmotic laxatives and stool softeners can assist constipation; for IBS-D, agents targeting bile acid signaling and gut secretion may be considered, alongside antimotility strategies for urgency. Neuromodulators—such as low-dose tricyclic antidepressants for pain and diarrhea modulation, or certain agents used for constipation and central pain pathways—are commonly used for refractory IBS, especially when visceral hypersensitivity dominates.
Psychological and behavioral therapies improve outcomes by addressing gut–brain signaling. Cognitive behavioral therapy, gut-directed hypnotherapy, and stress-management strategies have evidence for reducing symptom severity and healthcare utilization. These interventions are particularly relevant because symptom amplification is influenced by attention, threat perception, and maladaptive coping patterns.
For patients with persistent symptoms, escalation can include targeted therapies under specialist care, reassessment of diagnosis, and consideration of overlapping conditions like small intestinal bacterial overgrowth or pelvic floor dysfunction, though these require judicious testing to avoid unnecessary procedures. Long-term management focuses on maintaining remission, preventing relapse, and optimizing patient education about the functional nature of IBS while validating symptom burden.
Prognosis is variable: many patients have chronic or intermittent symptoms, but severity often stabilizes over time. Mortality is not increased for IBS itself, but comorbid psychiatric symptoms and reduced quality of life can be significant. The most evidence-based strategy combines accurate diagnosis, alarm-feature screening, phenotype-based medication, dietary trials, and behavioral therapy to address the mechanisms that link the gut to the central nervous system.
Source: [Creator/Source] @SPGEnergyAg
Agriculture by S&P Global Energy: Join S&P Global’s Energy CERA Agriculture & Food team for a live mid-year webinar update. – Iran, energy and fertilizers – direct impacts on costs and supply chains – Tariffs after IEEPA – Supply and price outlooks for crops and proteins. #breaking
— @SPGEnergyAg May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
